Psychotropic drug utilization in children with concurrent attention-deficit/hyperactivity disorder and anxiety

Journal of Anxiety Disorders

Volumn 28, Issue 6, 2014, Pages 530-536

  Liu, Xinyue ^a   Kubilis, Paul ^a   Xu, Dandan ^a   Bussing, Regina ^b   Winterstein, Almut G ^a,b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; CLONIDINE; DEXMETHYLPHENIDATE; FLUOXETINE; GUANFACINE; IMIPRAMINE; METHYLPHENIDATE; MIRTAZAPINE; NEUROLEPTIC AGENT; PAROXETINE; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

AGE; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; DRUG UTILIZATION; ETHNIC DIFFERENCE; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRESCHOOL CHILD; RACE DIFFERENCE; RISK BENEFIT ANALYSIS; SCHOOL CHILD; TREATMENT INDICATION;

ADOLESCENT; ANXIETY DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES;

EID: 84903443758     PISSN: 08876185     EISSN: 18737897     Source Type: Journal    
DOI: 10.1016/j.janxdis.2014.06.005     Document Type: Article

References (34)

1. AACAP Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry 2012, 51(1):98-113. 10.1016/j.jaac.2011.09.019.
2. AAP Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001, 108(4):1033-1044.
3. Abikoff H., McGough J., Vitiello B., McCracken J., Davies M., Walkup J., et al. Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. Journal of the American Academy of Child and Adolescent Psychiatry 2005, 44(5):418-427.
4. Biancosino B., Barbui C., Marmai L., Dona S., Grassi L. Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study. International Clinical Psychopharmacology 2005, 20(6):305-309.
5. Bloom B., Cohen R.A., Freeman G. Summary health statistics for U.S. children: National Health Interview Survey, 2010. Vital and Health Statistics 2011, 10(250):1-80.
6. CDC Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children - United States, 2003 and 2007. MMWR. Morbidity and Mortality Weekly Report 2010, 59(44):1439-1443.
7. Chavira D.A., Stein M.B., Bailey K., Stein M.T. Child anxiety in primary care: prevalent but untreated. Depression and Anxiety 2004, 20(4):155-164. 10.1002/da.20039.
8. Cohen J.A., Bukstein O., Walter H., Benson S.R., Chrisman A., Farchione T.R., et al. Practice parameter for the assessment and treatment of children and adolescents with posttraumatic stress disorder. Journal of the American Academy of Child and Adolescent Psychiatry 2010, 49(4):414-430.
9. Connolly S.D., Bernstein G.A. Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. Journal of the American Academy of Child and Adolescent Psychiatry 2007, 46(2):267-283. 10.1097/01.chi.0000246070.23695.06.
10. Connor D.F., Fletcher K.E., Swanson J.M. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 1999, 38(12):1551-1559. 10.1097/00004583-199912000-00017.
11. DMHMRSAS, V. ACP formulary and pocket guide to psychopharmacology 2005.
12. Farach F.J., Pruitt L.D., Jun J.J., Jerud A.B., Zoellner L.A., Roy-Byrne P.P. Pharmacological treatment of anxiety disorders: current treatments and future directions. Journal of Anxiety Disorders 2012, 26(8):833-843. 10.1016/j.janxdis.2012.07.009.
13. Garcia S.P., Guimaraes J., Zampieri J.F., Martinez A.L., Polanczyk G., Rohde L.A. Response to methylphenidate in children and adolescents with ADHD: does comorbid anxiety disorders matters?. Journal of Neural Transmission 2009, 116(5):631-636. 10.1007/s00702-009-0211-3.
14. Garnock-Jones K.P., Keating G.M. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatric Drugs 2009, 11(3):203-226. 10.2165/00148581-200911030-00005.
15. Geller D., Donnelly C., Lopez F., Rubin R., Newcorn J., Sutton V., et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. Journal of the American Academy of Child and Adolescent Psychiatry 2007, 46(9):1119-1127. 10.1097/chi.0b013e3180ca8385.
16. Gentile S. Efficacy of antidepressant medications in children and adolescents with obsessive-compulsive disorder: a systematic appraisal. Journal of Clinical Psychopharmacology 2011, 31(5):625-632. 10.1097/JCP.0b013e31822bb1ff.
17. Harpin V., Mazzone L., Raynaud J.P., Kahle J., Hodgkins P. Long-term outcomes of ADHD: a systematic review of self-esteem and social function. Journal of Attention Disorders 2013, 10.1177/1087054713486516.
18. Kratochvil C.J., Newcorn J.H., Arnold L.E., Duesenberg D., Emslie G.J., Quintana H., et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. Journal of the American Academy of Child and Adolescent Psychiatry 2005, 44(9):915-924. 10.1097/01.chi.0000169012.81536.38.
19. Larson K., Russ S.A., Kahn R.S., Halfon N. Patterns of comorbidity, functioning, and service use for US children with ADHD, 2007. Pediatrics 2011, 127(3):462-470. 10.1542/peds.2010-0165.
20. Maher A.R., Theodore G. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. Journal of Managed Care Pharmacy 2012, 18(5 Suppl. B):S1-S20.
21. March J.S., Swanson J.M., Arnold L.E., Hoza B., Conners C.K., Hinshaw S.P., et al. Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA). Journal of Abnormal Child Psychology 2000, 28(6):527-541.
22. Moreno M.A., Furtner F., Rivara F.P. Anxiety disorders in children and adolescents. Archives of Pediatrics & Adolescent Medicine 2010, 164(10):984. 10.1001/archpediatrics.2010.179.
23. Moshe K., Karni A., Tirosh E. Anxiety and methylphenidate in attention deficit hyperactivity disorder: a double-blind placebo-drug trial. Attention Deficit and Hyperactivity Disorders 2012, 4(3):153-158. 10.1007/s12402-012-0078-2.
24. MTA A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Archives of General Psychiatry 1999, 56(12):1073-1086.
25. Sallee F., Connor D.F., Newcorn J.H. A review of the rationale and clinical utilization of alpha2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related disorders. Journal of Child and Adolescent Psychopharmacology 2013, 23(5):308-319. 10.1089/cap.2013.0028.
26. Seixas M., Weiss M., Muller U. Systematic review of national and international guidelines on attention-deficit hyperactivity disorder. Journal of Psychopharmacology 2012, 26(6):753-765. 10.1177/0269881111412095.
27. Sparks J.A., Duncan B.L. Outside the black box: re-assessing pediatric antidepressant prescription. Journal of the Canadian Academy of Child and Adolescent Psychiatry 2013, 22(3):240-246.
28. Spencer T.J. Issues in the management of patients with complex attention-deficit hyperactivity disorder symptoms. CNS Drugs 2009, 23(Suppl. 1):9-20. 10.2165/00023210-200923000-00003.
29. Stolker J.J., Heerdink E.R., Leufkens H.G., Clerkx M.G., Nolen W.A. Determinants of multiple psychotropic drug use in patients with mild intellectual disabilities or borderline intellectual functioning and psychiatric or behavioral disorders. General Hospital Psychiatry 2001, 23(6):345-349.
30. Ter-Stepanian M., Grizenko N., Zappitelli M., Joober R. Clinical response to methylphenidate in children diagnosed with attention-deficit hyperactivity disorder and comorbid psychiatric disorders. Canadian Journal of Psychiatry 2010, 55(5):305-312.
31. Toteja N., Gallego J.A., Saito E., Gerhard T., Winterstein A., Olfson M., et al. Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment. The International Journal of Neuropsychopharmacology 2014, 17(7):1095-1105. 10.1017/S1461145712001320.
32. van der Oord S., Prins P.J., Oosterlaan J., Emmelkamp P.M. Treatment of attention deficit hyperactivity disorder in children. Predictors of treatment outcome. European Child & Adolescent Psychiatry 2008, 17(2):73-81. 10.1007/s00787-007-0638-8.
33. Visser S.N., Blumberg S.J., Danielson M.L., Bitsko R.H., Kogan M.D. State-based and demographic variation in parent-reported medication rates for attention-deficit/hyperactivity disorder, 2007-2008. Preventing Chronic Disease 2013, 10:E09. 10.5888/pcd9.120073.
34. Xiang Y.T., Weng Y.Z., Leung C.M., Tang W.K., Ungvari G.S. Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia. Pharmacopsychiatry 2007, 40(2):47-52. 10.1055/s-2007-970062.